Stempoint Capital »

Monte Rosa Therapeutics shares owned by Stempoint Capital

Quarter-by-quarter ownership of Monte Rosa Therapeutics (GLUE) shares owned by Stempoint Capital from 13F filings

Historical chart of Stempoint Capital investment in Monte Rosa Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Monte Rosa Therapeutics held by Stempoint Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Monte Rosa Therapeutics by Stempoint Capital

Quarter filed Position value Share count Share price at filing
2025-12-31 $966k 62k 15.68

More positions owned by Stempoint Capital

Abivax Sa Sponsored Ads (ABVX)
Scholar Rock Hldg Corp (SRRK)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Syndax Pharmaceuticals (SNDX)
Structure Therapeutics Sponsored Ads (GPCR)
Arcellx Common Stock (ACLX)
Roivant Sciences SHS (ROIV)
Terns Pharmaceuticals (TERN)
Twist Bioscience Corp (TWST)
Immunovant (IMVT)
Dyne Therapeutics (DYN)
Xenon Pharmaceuticals (XENE)
Surrozen Com New (SRZN)
Celcuity (CELC)
Mineralys Therapeutics (MLYS)

View all positions for Stempoint Capital

Top funds holding Monte Rosa Therapeutics

NEA Management Company
BVF
Baker Bros. Advisors
TCG Crossover Management
Versant Venture Management
BlackRock
Suvretta Capital Management
Vanguard Group
FMR
State Street Corporation
Aisling Capital Management
American Century Companies
Geode Capital Management
MPM Oncology Impact Management
Silverarc Capital Management

View all funds holding Monte Rosa Therapeutics